Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients

Conclusions:
A fixed treatment scheme of rituximab, with re-treatment every 6 months, was efficacious for NMO and NMOSD, with a good safety profile; however, to obtain an even better benefit-risk ratio, close monitoring of CD19+ B cells should be performed before the re-treatment of patients with high-level disability, concomitant leukopenia and hypogammaglobulinemia.

Source: Multiple Sclerosis - March 17, 2016 Category: Neurology Authors: Radaelli, M., Moiola, L., Sangalli, F., Esposito, F., Barcella, V., Ferre, L., Rodegher, M., Colombo, B., Fazio, R., Martinelli, V., Comi, G. Tags: Original Research Papers Source Type: research